GATB

Across TCGA pan-cancer cohorts, GATB mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated GATB data layer compared with 23 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher GATB mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated GATB expression acts as an unfavorable survival marker, although some lineages such as LSCC and CCRCC show a favorable association.

LSCC and CCRCC are the cancer types where GATB mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	OS	Tertile	II,III,IV	0.920	0.644	.005	26	view →
CCRCC	DFS	Tertile	All	1.000	0.504	.007	7	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

GATB–LSCC (OS)

Open the LSCC breakdown →